Check-Cap Ltd CHEK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CHEK is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $2.27
- Day Range
- $2.22–2.30
- 52-Week Range
- $1.27–4.63
- Bid/Ask
- $2.21 / $2.30
- Market Cap
- $13.37 Mil
- Volume/Avg
- 22,718 / 274,707
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Value
- Total Number of Employees
- 85
- Website
- https://www.check-cap.com
Valuation
|
Metric
|
CHEK
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.49 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
CHEK
Financial Strength
|
Metric
|
CHEK
|
|---|---|
Quick Ratio | 17.17 |
Current Ratio | 17.60 |
Interest Coverage | — |
Quick Ratio
CHEK
Profitability
|
Metric
|
CHEK
|
|---|---|
Return on Assets (Normalized) | −40.45% |
Return on Equity (Normalized) | −44.52% |
Return on Invested Capital (Normalized) | −48.95% |
Return on Assets
CHEK
Diagnostics & Research Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Ylgntlvt | Msdl | $209.3 Bil | |
DHR
| Danaher Corp | Mbtrgsbtw | Cdxrgm | $182.1 Bil | |
IQV
| IQVIA Holdings Inc | Bwnykdb | Hsnpx | $42.8 Bil | |
IDXX
| IDEXX Laboratories Inc | Vrjpxmjrgm | Jywbgy | $41.5 Bil | |
A
| Agilent Technologies Inc | Fdrmpqytyn | Wbpt | $40.4 Bil | |
MTD
| Mettler-Toledo International Inc | Pxzydqskp | Qpgbl | $26.5 Bil | |
ICLR
| Icon PLC | Pgdjpwsh | Ltjnwl | $24.8 Bil | |
ILMN
| Illumina Inc | Hhrnjxzn | Zwlcfn | $19.5 Bil | |
WAT
| Waters Corp | Chxxqdycs | Wqbr | $18.5 Bil | |
LH
| Laboratory Corp of America Holdings | Msbwcwqxz | Pzkncz | $16.7 Bil |